Venous thromboembolism and mortality associated with tranexamic acid use during total hip and knee arthroplasty

Christopher M. Duncan; Blake P. Gillette; Adam K. Jacob; Rafael J. Sierra; Joaquin Sanchez-Sotelo; Hugh M. Smith

doi:10.1016/j.arth.2014.08.022

Venous thromboembolism and mortality associated with tranexamic acid use during total hip and knee arthroplasty

Christopher M. Duncan, Blake P. Gillette, Adam K. Jacob, Rafael J. Sierra, Joaquin Sanchez-Sotelo, Hugh M. Smith

Orthopedic Surgery

Research output: Contribution to journal › Article › peer-review

66 Scopus citations

Abstract

TKA and THA are associated with blood transfusion and risk for postoperative venothromboembolism (VTE). Reports show that tranexamic acid (TA) may be safe to use in high-risk orthopedic patients, but further data are needed to substantiate its use. All patients who underwent primary or revision TKA or THA in a five year period were retrospectively identified. In 13,262 elective TKA or THA procedures, neither the odds of VTE (OR = 0.98; 95% CI 0.67-1.45; P = 0.939) or adjusted odds of death (OR = 0.26; 95% CI 0.04-1.80; P = 0.171) were significant with TA administration. The major findings of this large, single center, retrospective cohort study show the odds of postoperative VTE and 30-day mortality were unchanged with TA administration.

Original language	English (US)
Pages (from-to)	272-276
Number of pages	5
Journal	Journal of Arthroplasty
Volume	30
Issue number	2
DOIs	https://doi.org/10.1016/j.arth.2014.08.022
State	Published - Feb 1 2015

Keywords

Hip arthroplasty
Knee arthroplasty
Mortality
Tranexamic acid
Venothromboembolism

ASJC Scopus subject areas

Orthopedics and Sports Medicine

Access to Document

10.1016/j.arth.2014.08.022

Cite this

@article{a5244a2fe0244e08b8ebea6ee7b7b999,

title = "Venous thromboembolism and mortality associated with tranexamic acid use during total hip and knee arthroplasty",

abstract = "TKA and THA are associated with blood transfusion and risk for postoperative venothromboembolism (VTE). Reports show that tranexamic acid (TA) may be safe to use in high-risk orthopedic patients, but further data are needed to substantiate its use. All patients who underwent primary or revision TKA or THA in a five year period were retrospectively identified. In 13,262 elective TKA or THA procedures, neither the odds of VTE (OR = 0.98; 95% CI 0.67-1.45; P = 0.939) or adjusted odds of death (OR = 0.26; 95% CI 0.04-1.80; P = 0.171) were significant with TA administration. The major findings of this large, single center, retrospective cohort study show the odds of postoperative VTE and 30-day mortality were unchanged with TA administration.",

keywords = "Hip arthroplasty, Knee arthroplasty, Mortality, Tranexamic acid, Venothromboembolism",

author = "Duncan, {Christopher M.} and Gillette, {Blake P.} and Jacob, {Adam K.} and Sierra, {Rafael J.} and Joaquin Sanchez-Sotelo and Smith, {Hugh M.}",

note = "Publisher Copyright: {\textcopyright} 2014 Elsevier Inc.",

year = "2015",

month = feb,

day = "1",

doi = "10.1016/j.arth.2014.08.022",

language = "English (US)",

volume = "30",

pages = "272--276",

journal = "Journal of Arthroplasty",

issn = "0883-5403",

publisher = "Churchill Livingstone",

number = "2",

}

TY - JOUR

T1 - Venous thromboembolism and mortality associated with tranexamic acid use during total hip and knee arthroplasty

AU - Duncan, Christopher M.

AU - Gillette, Blake P.

AU - Jacob, Adam K.

AU - Sierra, Rafael J.

AU - Sanchez-Sotelo, Joaquin

AU - Smith, Hugh M.

PY - 2015/2/1

Y1 - 2015/2/1

N2 - TKA and THA are associated with blood transfusion and risk for postoperative venothromboembolism (VTE). Reports show that tranexamic acid (TA) may be safe to use in high-risk orthopedic patients, but further data are needed to substantiate its use. All patients who underwent primary or revision TKA or THA in a five year period were retrospectively identified. In 13,262 elective TKA or THA procedures, neither the odds of VTE (OR = 0.98; 95% CI 0.67-1.45; P = 0.939) or adjusted odds of death (OR = 0.26; 95% CI 0.04-1.80; P = 0.171) were significant with TA administration. The major findings of this large, single center, retrospective cohort study show the odds of postoperative VTE and 30-day mortality were unchanged with TA administration.

AB - TKA and THA are associated with blood transfusion and risk for postoperative venothromboembolism (VTE). Reports show that tranexamic acid (TA) may be safe to use in high-risk orthopedic patients, but further data are needed to substantiate its use. All patients who underwent primary or revision TKA or THA in a five year period were retrospectively identified. In 13,262 elective TKA or THA procedures, neither the odds of VTE (OR = 0.98; 95% CI 0.67-1.45; P = 0.939) or adjusted odds of death (OR = 0.26; 95% CI 0.04-1.80; P = 0.171) were significant with TA administration. The major findings of this large, single center, retrospective cohort study show the odds of postoperative VTE and 30-day mortality were unchanged with TA administration.

KW - Hip arthroplasty

KW - Knee arthroplasty

KW - Mortality

KW - Tranexamic acid

KW - Venothromboembolism

UR - http://www.scopus.com/inward/record.url?scp=84925042467&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84925042467&partnerID=8YFLogxK

U2 - 10.1016/j.arth.2014.08.022

DO - 10.1016/j.arth.2014.08.022

M3 - Article

C2 - 25257237

AN - SCOPUS:84925042467

SN - 0883-5403

VL - 30

SP - 272

EP - 276

JO - Journal of Arthroplasty

JF - Journal of Arthroplasty

IS - 2

ER -

Venous thromboembolism and mortality associated with tranexamic acid use during total hip and knee arthroplasty

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this